Your browser doesn't support javascript.
loading
Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia
Silva, Rita Santos; Carvalho, Berta; Pedro, Jorge; Castro-Correia, Cíntia; Carvalho, Davide; Carvalho, Filipa; Fontoura, Manuel.
Afiliação
  • Silva, Rita Santos; Universidade do Porto. Faculdade de Medicina. Centro Hospitalar Universitário S. João. PT
  • Carvalho, Berta; Universidade do Porto. Faculdade de Medicina. Departamento de Patologia. PT
  • Pedro, Jorge; Universidade do Porto. Instituto de Investigação e Inovação em Saúde. Faculdade de Medicina. PT
  • Castro-Correia, Cíntia; Universidade do Porto. Faculdade de Medicina. Centro Hospitalar Universitário S. João. PT
  • Carvalho, Davide; Universidade do Porto. Instituto de Investigação e Inovação em Saúde. Faculdade de Medicina. PT
  • Carvalho, Filipa; Universidade do Porto. Faculdade de Medicina. Departamento de Patologia. PT
  • Fontoura, Manuel; Universidade do Porto. Faculdade de Medicina. Centro Hospitalar Universitário S. João. PT
Arch. endocrinol. metab. (Online) ; 66(2): 168-175, Apr. 2022. tab, graf
Article em En | LILACS-Express | LILACS | ID: biblio-1374261
Biblioteca responsável: BR1.1
ABSTRACT
ABSTRACT

Objective:

CYP21A2 mutation heterozygote carriers seem to have an increased risk of hyperandrogenism. However, the clinical relevance of the heterozygote carrier status and the reliability of hormonal testing in discriminating a carrier from a non-carrier are puzzling questions. We aimed to characterize a population of Portuguese females suspected of having non-classic congenital adrenal hyperplasia (NC-CAH) due to clinical and biochemical criteria and who have undergone CYP21A2 molecular analysis. Subjects and

methods:

Retrospectively, we have analyzed the clinical records of 131 females (32 girls aged 3-9 and 99 adolescents and premenopausal women aged 13-49) who underwent complete CYP21A2 molecular analysis due to suspicion of NC-CAH. We divided included participants into three groups according to the CYP21A2 molecular

analysis:

NC-CAH females (46), heterozygous carriers (49), and wild type (36). We then compared clinical signs and symptoms as well as biochemical and molecular data between carriers and NC-CAH individuals and between carriers and wild type females. We measured 17OHP by electrochemiluminescence immunoassay.

Results:

Clinical features were similar between groups. Heterozygous carriers presented higher basal and post-cosyntropin 17-hydroxyprogesterone (17OHP) than wild type individuals (p < 0.05) and lower basal and stimulated 17OHP levels than NC-CAH patients (p < 0.05). We discovered a considerable overlap between 17OHP levels among groups. The most common pathogenic variant we identified was p.Val282Leu.

Conclusion:

In this population of hyperandrogenic women and children, heterozygous carriers showed higher basal and stimulated 17OHP than non-carriers although normal basal and stimulated 17OHP responses do not exclude heterozygosity for CYP21A2 pathogenic variants. In this study, only the molecular analysis presented good sensitivity in identifying heterozygotes.
Palavras-chave

Texto completo: 1 Base de dados: LILACS Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Portugal

Texto completo: 1 Base de dados: LILACS Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Portugal